Wegovy Compounding Legal Status: What Patients and Prescribers Need to Know in 2025
A clinician-reviewed guide to the FDA approval history, compounding legal status, label requirements, and post-market safety data for Wegovy (semaglutide 2.4 mg).
WEGOVY: Regulatory History
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
6articles
4topic areas covered
Jul 10, 2025latest review
WEGOVY: Regulatory History library
Showing 6 of 6 clinical reviews.
Wegovy FAERS Safety Signals: What Post-Market Surveillance Data Actually Show
An evidence-based review of Wegovy (semaglutide 2.4 mg) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including GI events, pancreatitis, thyroid neoplasms, and gallbladder disorders.
Wegovy FDA Approval History: Timeline, Label Changes, and Safety Updates
A complete timeline of Wegovy (semaglutide 2.4 mg) FDA approval, label expansions, post-market safety signals, and regulatory milestones from 2021 through 2026.
Wegovy Global Regulatory Status: FDA Approval, EMA Authorization, and Worldwide Access in 2026
A comprehensive review of Wegovy (semaglutide 2.4 mg) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and current prescribing status across major markets.
Wegovy Legal and Patent Challenges: FDA History, Litigation, and Market Exclusivity
A clinical review of Wegovy's regulatory path, patent disputes, legal challenges from compounding pharmacies, and the evolving FDA label for semaglutide 2.4 mg.
Wegovy Pipeline and Next-Gen GLP-1 Therapies: What Comes After Semaglutide 2.4 mg
A clinical review of the Wegovy regulatory timeline, current label, post-market safety data, and the next-generation GLP-1 and multi-agonist drugs in development that may succeed semaglutide 2.4 mg.